Tizanidine for Movement Control After Stroke

This study is looking at how a medication called Tizanidine (Zanaflex®) affects arm movement in people who have had a stroke. Tizanidine is already approved to help with muscle stiffness (spasticity). Researchers want to understand how Tizanidine changes arm movements, eye responses, and brain activity. You might be able to join if you are between 18 and 80 years old, had a stroke at least six months ago that affected one side of your body, and still have some arm weakness but can move your arm a little. The study will measure things like how high you can lift your arm, how your brain and muscles work together, and how far you can reach. Understanding these changes could help improve rehabilitation for stroke survivors.

Study design
This is a randomized, double-blind study with 64 participants. You will receive both Tizanidine and a placebo (an inactive substance) at different times.
What's involved
You will have one brain MRI and participate in 6 arm/hand experiments on separate days, at least one week apart. During each experiment, you will complete tasks before and 1.5 hours after taking either Tizanidine or the placebo.
Compensation
Not stated in the trial record.
Follow-up
Measurements are taken before and 1.5 hours after medication administration during each experimental session.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06666673

Effect of Neural Constraints on Movement in Stroke

Recruiting
EARLY_PHASE1Ages 18–80InterventionalBasic science
Northwestern University
~64 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:TizanidinePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Brace Height
Measured over Before and 1.5 hours after administration of TIZ
+3 more outcomes measured
Stroke

NCT06666673

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100

    Chicago, Illinoisstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Julius Dewald, DPT, PhD · PRINCIPAL_INVESTIGATOR · Northwestern University
  • Jun Yao, PhD · PRINCIPAL_INVESTIGATOR · Northwestern University

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment
Age between 18-80
Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50/66)
Ability to communicate, understand, and provide informed consent
Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension
MRI compatible
Intact skin on the hemiparetic arm
Ability to sit for three hours.

Exclusion

Motor or sensory impairment in the non-affected limb (FMA\<66, filament \>3.6)
Any brainstem and/or cerebellar lesion
untreated cardiovascular disease
History of neurologic disorder other than stroke that affects the arms
Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale
Current use of a pacemaker
History of seizure
Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol/alcohol injections \<12 months before participation
Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes
Current participation in any experimental rehabilitation or drug studies
Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity
pregnant women or women who are nursing.
  • Brace HeightBefore and 1.5 hours after administration of TIZ

    Brace height quantifies the amplification in motor unit discharge rate generated by PICs. Brace height is sensitive to the level of neuromodulatory drive received by motoneurons.

  • Cortico-muscular-coherence in beta bandBefore and 1.5 hours after administration of TIZ

    Cortico-muscular coherence (CMC) is a commonly used method to measure the synchronized activity between cortex and muscles. Specifically, betaband CMC has been reported to be linked to the use of corticospinal tract.

  • Difference in reaching distance under shoulder abduction loadBefore and 1.5 hours after administration of TIZ

    The difference in reaching distance under shoulder abduction (SABD) load measures the strength of flexion synergy.

  • Reflexive electromyograph activity prior to movementBefore and 1.5 hours after administration of TIZ

    Reflexive electromyograph (EMG) activity will be calculated as the difference between perturbation-induced EMG amplitude and baseline EMG, averaged during three-time windows 1) before the perturbation -100- 0 ms pre-perturbation; 2) 25 - 75 ms (shortlatency stretch reflex) and 2) 75 - 125 ms (long latency stretch reflex) after the perturbation onset. Perturbations occur at rest before the onset of a regular ballistic reaching trial. EMG is then normalized by the maximal EMG of the corresponding muscle.